AI and Cancer Research ── Cancer biology ── 2026-11-17

Cancer molecular biology and AI
- Abstract
Heterogeneity in tumor regulatory programs, cellular composition and spatial organization complicates target prioritization for natural compounds. We developed a spatial-context heterogeneous graph neural network ranker (SC-HGNN-Rank) that combines relation-aware graph representations with ranking optimization to integrate compound-target associations, transcriptional regulation, interaction networks, and single-cell and spatial information. The model ranked 600 candidate axes in colon adenocarcinoma (COAD), hepatocellular carcinoma (LIHC) and gastric adenocarcinoma (STAD). Under matched training conditions, mean Spearman correlations with the reference ranking were 0.965, 0.967 and 0.976 for leave-one-cancer-out, compound-group holdout and target-group holdout evaluations, respectively. The composite ranking objective improved mean Spearman correlation by 0.049 over a simple objective using the same encoder, whereas removing the spatial module reduced it by 0.147. Model ranking and multilayer evidence prioritized Quercetin-CDK1/MYB-Myeloid in COAD, 4',5-dihydroxyflavone (4',5-DHF)-AR/HDAC1-T/NK in LIHC, and Eriodyctiol-HSP90AB1/HOPX-Fibroblast in STAD. Expanded spatial analyses with expression-matched gene controls assessed associations between target expression and mapped cell abundance. Cellular thermal shift and drug affinity responsive target stability assays showed increased retention of target proteins after compound treatment. In HCT116, JHH-6 and MKN45 cells, the compounds reduced viability, colony formation, migration and invasion cell counts, and increased apoptosis. Target knockdown produced similar growth-inhibitory phenotypes, whereas overexpression attenuated compound-induced effects, supporting the involvement of CDK1, AR and HSP90AB1 in the respective responses. The accompanying Explorer supports candidate searches, evidence inspection and data export. By incorporating regulatory and spatial contexts into natural-compound prioritization, this study provides a reusable approach and experimentally supported candidates for target-directed pharmacological research in digestive system cancers.
Journal IF-equivalent: 11.5 (OpenAlex 2-year mean citedness, value as of 2026-11-16, retrieved 2026-11-17; not the official Clarivate IF)Reference: Jiang H, Zheng S, Yang C, Zhang X, Liu H, Bao Y. Graph learning guided by regulatory and spatial contexts prioritizes natural compound–target pairs in digestive system cancers. Pharmacol Res. 2026 Nov [Epub ahead of print]. doi:10.1016/j.phrs.2026.109767. PMID: 43035199.Checked: Abstract only - Abstract
Accurate peptide-HLA class I binding prediction is fundamental for identifying tumor neoantigens and advancing personalized immunotherapy. We present LKMHCpan, a pan-specific predictor that leverages transformer networks to optimize HLA-I pseudo-sequences representation through attention-guided integration of 88 key residues primarily within the α1, α2, and α3 domains. LKMHCpan achieves a mean precision-recall area under the curve (PR-AUC) of 0.93, generalizes robustly to untrained HLA-I alleles, and supports peptides longer than 11 amino acids. In Tumor Neoantigen Selection Alliance (TESLA) data, LKMHCpan identified 94% of immunogenic neoantigens with strong score-immunogenicity correlation. Neoantigen burden from LKMHCpan significantly stratified clinical outcomes in two immunotherapy-treated cohorts: metastatic melanoma ( n = 73) and lung cancer ( n = 309), with high-burden patients exhibiting clinical benefit. Its ability to resolve binding motifs for untrained alleles and single-amino-acid HLA-I mutants highlights its potential for elucidating complex peptide-major histocompatibility complex (MHC) interactions. LKMHCpan provides a scalable framework for neoantigen discovery and prognostic assessment in precision immunotherapy.
Journal IF-equivalent: 5.3 (OpenAlex 2-year mean citedness, value as of 2026-11-16, retrieved 2026-11-17; not the official Clarivate IF)Reference: Li Q, Liu S, Yao M, Chen H, Yu Y, Zhang B, et al. LKMHCpan: Transformer-optimized HLA-I pseudo-sequences enhance neoantigen prediction for immunotherapy. iScience. 2026 Nov;29(11):118134. doi:10.1016/j.isci.2026.118134. PMID: 43034688.Checked: Abstract only